NCT02068586 2026-03-16
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Thomas Jefferson University
Phase 2 Active not recruiting
Clinical Trials
17 trialsNCT06432660 2026-02-06
PROMPT
Duke University
Active not recruiting
NCT04645680 2026-01-30
DIET
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06075589 2026-01-15
Psychoeducation for Uveal Melanoma
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
NCT03025256 2026-01-08
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05628883 2026-01-07
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT05075993 2025-12-26
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05282901 2025-11-24
PLUME
Institut Curie
Phase 2 Active not recruiting
NCT05170334 2025-10-01
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04283890 2025-09-09
CHOPIN
Leiden University Medical Center
Phase 1/2 Active not recruiting
NCT04588662 2025-08-22
A Prospective Natural History Study in Uveal Melanoma
Columbia University
Active not recruiting
NCT04728633 2025-08-06
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
Thomas Jefferson University
Phase 2 Active not recruiting
NCT05341349 2025-07-30
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Phase 1 Active not recruiting
NCT05308901 2025-07-25
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Providence Health & Services
Phase 2 Active not recruiting
NCT05315258 2025-07-17
TebeMRD
University of Oxford
Phase 2 Active not recruiting
NCT05187884 2025-06-24
NADOM
St Vincent's Hospital, Sydney
Phase 2 Active not recruiting
NCT06863870 2025-03-07
Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Active not recruiting